Insider Selling: Orchestra BioMed (NASDAQ:OBIO) Insider Sells $61,350.00 in Stock

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) insider Darren Sherman sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $4.09, for a total transaction of $61,350.00. Following the completion of the transaction, the insider owned 1,154,327 shares of the company’s stock, valued at approximately $4,721,197.43. This trade represents a 1.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Darren Sherman also recently made the following trade(s):

• On Monday, June 1st, Darren Sherman sold 15,000 shares of Orchestra BioMed stock. The shares were sold at an average price of $3.87, for a total transaction of $58,050.00.

Orchestra BioMed Trading Down 1.7%

Shares of NASDAQ OBIO opened at $4.15 on Friday. The firm has a 50 day moving average price of $3.97 and a two-hundred day moving average price of $4.10. The stock has a market cap of $248.50 million, a P/E ratio of -4.28 and a beta of 0.50. Orchestra BioMed Holdings, Inc. has a 52-week low of $2.20 and a 52-week high of $5.42. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03.

Orchestra BioMed (NASDAQ:OBIO) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. The company had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.92 million. As a group, equities analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.47 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of OBIO. Alyeska Investment Group L.P. acquired a new position in shares of Orchestra BioMed during the third quarter valued at about $3,386,000. Pathstone Holdings LLC acquired a new stake in shares of Orchestra BioMed in the 3rd quarter valued at about $2,495,000. Vanguard Group Inc. increased its position in Orchestra BioMed by 28.0% in the 3rd quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company’s stock valued at $3,675,000 after buying an additional 324,558 shares in the last quarter. Simplify Asset Management Inc. acquired a new position in Orchestra BioMed during the 1st quarter worth approximately $932,000. Finally, 683 Capital Management LLC bought a new position in Orchestra BioMed in the fourth quarter worth approximately $847,000. 53.20% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on OBIO. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Orchestra BioMed in a research note on Thursday, May 14th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Friday, July 17th. B. Riley Financial reduced their target price on Orchestra BioMed from $12.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Barclays increased their target price on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an “overweight” rating in a research report on Wednesday, May 13th. Finally, Wall Street Zen lowered shares of Orchestra BioMed from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Orchestra BioMed currently has a consensus rating of “Moderate Buy” and an average target price of $13.60.

About Orchestra BioMed

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.